|Table of Contents|

Molecular genetics characterization and prognostic analysis of adult acute myeloid leukemia in China

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 04
Page:
703-708
Research Field:
Publishing date:

Info

Title:
Molecular genetics characterization and prognostic analysis of adult acute myeloid leukemia in China
Author(s):
WANG Wanyue; LI Yujiao; LI Yongli; LI Xiaoming
Department of Hematology,the Affiliated Hospital of Southwest Medical University,Sichuan Luzhou 646000,China.
Keywords:
acute myeloid leukemia; chromosome aberration; genetic mutation; prognosis
PACS:
R733.71
DOI:
10.3969/j.issn.1672-4992.2024.04.020
Abstract:
Objective:To investigate the molecular genetics characterization and prognostic factors of acute myeloid leukemia (AML).Methods:We retrospectively analyzed the clinical data of 160 newly diagnosed AML patients,and used conventional G-banding technique for chromosomal karyotypes.Real-time fluorescence quantitative polymerase chain reaction (PCR) was used to detect fusion genes,and DNA sequencing was used to detect mutations,and COX regression analysis and Kaplan-Meier survival curve were used to analyze the probable factors influencing the overall survival (OS) of the patients.Results:Among 160 AML patients,74 patients (46.2%) had abnormal chromosomal karyotypes,15 patients (9.4%) had complex karyotypes,and 18 patients (11.3%) had monosomal karyotypes.The top five genes with the highest mutation frequencies among the 160 patients were,in order,WT1 (22.5%),NPM1 (16.9%),DNMT3A (16.9%),CEBPA (15.0%),and FLT3-ITD (15.0%).Those with mutations in DNMT3A,FLT3,IDH2,and RUNX1 genes had a shorter survival compared to those with no DNMT3A,FLT3,IDH2,and RUNX1 mutation (P＜0.05),and those with CEBPA gene mutations had prolonged survival compared to those without CEBPA mutations (P＜0.05).Multivariate regression analysis showed that failure to reach CR after initial induction,no transplantation,adverse prognostic group,with DNMT3A mutation,and with FLT3 mutation were independent poor prognostic factors for OS in AML patients.Conclusion:Chromosomal abnormalities and gene mutations were common in 160 AML patients,and the prognosis was related to molecular genetics characterization,treatment response and transplantation.

References:

[1] WU M,LI C,ZHU X.FLT3 inhibitors in acute myeloid leukemia［J］.J Hematol Oncol,2018,11(1):133.
[2] ISSA GC,DINARDO CD.Acute myeloid leukemia with IDH1 and IDH2 mutations:2021 treatment algorithm［J］.Blood Cancer J,2021,11(6):107.
[3] LACHOWIEZ C,DINARDO CD,KONOPLEVA M.Venetoclax in acute myeloid leukemia - current and future directions［J］.Leuk Lymphoma,2020,61(6):1313-1322.
[4] PADMAKUMAR D,CHANDRAPRABHA VR,GOPINATH P,et al.A concise review on the molecular genetics of acute myeloid leukemia［J］.Leuk Res,2021,111:106727.
[5] 中华医学会血液学分会白血病淋巴瘤学组.中国成人急性髓系白血病（非急性早幼粒细胞白血病）诊疗指南（2021年版）［J］.中华血液学杂志,2021,42(8):617-623. Leukemia & Lymphoma Group,Chinese Society of Hematology,Chinese Medical Association.Chinese guidelines for the diagnosis and treatment of adult acute myeloid leukemia(notAPL)(2021)［J］.Chin J Hematol,2021,42(8):617-623.
[6] DUNCAVAGE EJ,BAGG A,HASSERJIAN RP,et al.Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia［J］.Blood,2022,140(21):2228-2247.
[7] KAYSER S,LEVIS MJ.The clinical impact of the molecular landscape of acute myeloid leukemia［J］.Haematologica,2023,108(2):308-320.
[8] 魏计锋,仇惠英,陈泽,等.RAS基因突变在急性髓系白血病患者中的临床意义［J］.中国实验血液学杂志,2022,30(05):1391-1396. WEI JF,QIU HY,CHEN Z,et al.Clinical significance of RAS gene mutations in patients with acute myeloid leukemia［J］.Journal of Experimental Hematology,2022,30(05):1391-1396.
[9] 周柰岑,郭欢绪,郭怀鹏,等.伴NRAS基因突变的急性髓系白血病患者的临床特征及生存分析［J］.现代肿瘤医学,2022,30(22):4166-4170. ZHOU NC,GUO HX,GUO HP,et al.Clinical characteristics and survival and alysis of acute myeloid leukemia patients with NRAS gene mutation［J］.Modern Oncology,2022,30(22):4166-4170.
[10] BYRD JC,MRZEK K,DODGE RK,et al.Pretreatment cytogenetic abnormalities are predictive of induction success,cumulative incidence of relapse,and overall survival in adult patients with de novo acute myeloid leukemia:results from Cancer and Leukemia Group B (CALGB 8461)［J］.Blood,2002,100(13):4325-4336.
[11] GRIMWADE D,WALKER H,OLIVER F,et al.The importance of diagnostic cytogenetics on outcome in AML:analysis of 1,612 patients entered into the MRC AML 10 trial.The Medical Research Council Adult and Children's Leukaemia Working Parties［J］.Blood,1998,92(7):2322-2333.
[12] MEDEIROS BC,OTHUS M,FANG M,et al.Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia:the Southwest Oncology Group (SWOG) experience［J］.Blood,2010,116(13):2224-2228.
[13] BREEMS DA,VAN PUTTEN WL,DE GREEF GE,et al.Monosomal karyotype in acute myeloid leukemia:a better indicator of poor prognosis than a complex karyotype［J］.J Clin Oncol,2008,26(29):4791-4797.
[14] PATEL JP,GNEN M,FIGUEROA ME,et al.Prognostic relevance of integrated genetic profiling in acute myeloid leukemia［J］.N Engl J Med,2012,366(12):1079-1089.
[15] LEY TJ,DING L,WALTER MJ,et al.DNMT3A mutations in acute myeloid leukemia［J］.N Engl J Med,2010,363(25):2424-2433.
[16] HEROLD T,ROTHENBERG-THURLEY M,GRUNWALD VV,et al.Validation and refinement of the revised 2017 European Leukemia Net genetic risk stratification of acute myeloid leukemia［J］.Leukemia,2020,34(12):3161-3172.
[17] KENNEDY VE,SMITH CC.FLT3 mutations in acute myeloid leukemia:key concepts and emerging controversies［J］.Front Oncol,2020,10:612880.
[18] BIENZ M,LUDWIG M,LEIBUNDGUT EO,et al.Risk assessment in patients with acute myeloid leukemia and a normal karyotype［J］.Clin Cancer Res,2005,11(4):1416-1424.
[19] FRHLING S,SCHLENK RF,BREITRUCK J,et al.Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics:a study of the AML Study Group Ulm［J］.Blood,2002,100(13):4372-4380.
[20] HALAHLEH K,TAQASH A,ABDELKHALEQ H,et al.Analysis of FLT3-activating mutations in patients with acute myelogenous leukemia in Jordan:Association with FAB subtypes and identification of subgroups with poor prognosis［J］.Clin Lymphoma Myeloma Leuk,2021,21(7):e588-e597.
[21] YOKOTA A,HUO L,LAN F,et al.The clinical,molecular,and mechanistic basis of RUNX1 mutations identified in hematological malignancies［J］.Mol Cells,2020,43(2):145-152.
[22] MONTALBAN-BRAVO G,DINARDO CD.The role of IDH mutations in acute myeloid leukemia［J］.Future Oncol,2018,14(10):979-993.
[23] THOL F,GANSER A.Treatment of relapsed acute myeloid leukemia［J］.Curr Treat Options Oncol,2020,21(8):66.
[24] SAAD A,DE LIMA M,ANAND S,et al.Hematopoietic cell transplantation,version 2.2020,NCCN clinical practice guidelines in oncology［J］.J Natl Compr Canc Netw,2020,18(5):599-634.

Memo

Memo:
四川省重点研发项目（编号：2019YFS0301）；四川省泸州市科技局应用基础研究项目(编号：2019LZXNYDJ54)
Last Update: 1900-01-01